Ultragenyx Pharmaceutical (RARE) Equity Ratio (2016 - 2025)
Ultragenyx Pharmaceutical (RARE) has disclosed Equity Ratio for 10 consecutive years, with 0.05 as the latest value for Q4 2025.
- On a quarterly basis, Equity Ratio fell 130.78% to 0.05 in Q4 2025 year-over-year; TTM through Dec 2025 was 0.05, a 130.78% decrease, with the full-year FY2025 number at 0.05, down 130.78% from a year prior.
- Equity Ratio was 0.05 for Q4 2025 at Ultragenyx Pharmaceutical, down from 0.01 in the prior quarter.
- In the past five years, Equity Ratio ranged from a high of 0.66 in Q1 2021 to a low of 0.05 in Q4 2025.
- A 5-year average of 0.28 and a median of 0.2 in 2023 define the central range for Equity Ratio.
- Peak YoY movement for Equity Ratio: skyrocketed 780.18% in 2024, then tumbled 130.78% in 2025.
- Ultragenyx Pharmaceutical's Equity Ratio stood at 0.61 in 2021, then tumbled by 62.41% to 0.23 in 2022, then dropped by 19.02% to 0.18 in 2023, then decreased by 8.01% to 0.17 in 2024, then crashed by 130.78% to 0.05 in 2025.
- Per Business Quant, the three most recent readings for RARE's Equity Ratio are 0.05 (Q4 2025), 0.01 (Q3 2025), and 0.12 (Q2 2025).